19:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Adlai Nortye gets rights to buparlisib from Novartis

Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to develop and commercialize buparlisib,...
19:47 , Jul 10, 2018 |  BC Extra  |  Company News

Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to develop...
19:15 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest inhibiting NEK9 or MAP2K4 could help treat PI3K inhibitor-resistant triple-negative breast cancer (TNBC). In tumor samples from patient-derived xenograft (PDX) mouse models of TNBC, levels of NEK9 and MAP2K4...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human cerebral...
18:09 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting GLI1 alone or in combination with PI3K could help treat squamous cell carcinoma (SCC) of the lung. In lung tissue samples from patients, GLI1...
16:00 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2, TACC1, ZAK, ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast cancer cell line treated...
07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , Jun 13, 2016 |  BioCentury  |  Product Development

Basket cases

Both the Genentech Inc. unit of Roche and Novartis AG are using basket trials to study targeted cancer agents more efficiently. Genentech's initial forays could yield rare subpopulation data to bring its marketed therapies into...
07:00 , May 23, 2016 |  BioCentury  |  Strategy

Two heads are better

With Gleevec imatinib off patent, flagging ophthalmics sales and at least one slower than expected launch, Novartis AG is consolidating operations at the top to cut costs, while also splitting its R&D into two buckets:...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Binimetinib: Preliminary Phase II data

Preliminary data from 40 BRAF and MEK inhibitor-naive patients with locally advanced or metastatic BRAF V600 mutation-positive melanoma in Group A of Part 1 of the 2-part, open-label, international Phase II LOGIC2 trial showed that...